Literature DB >> 25869078

Enhancing postmarketing surveillance: continuing challenges.

Dustin D French1,2, Curtis E Margo3, Robert R Campbell4,5.   

Abstract

Mesh：

Year:  2015        PMID： 25869078      PMCID： PMC4594697          DOI： 10.1111/bcp.12658

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Rooting out institutional corruption to manage inappropriate off-label drug use.

Authors:  Marc A Rodwin
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

2.  Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.

Authors:  Jean-David Zeitoun; Jérémie H Lefèvre; Nicholas S Downing; Henri Bergeron; Joseph S Ross
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

3.  Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.

Authors:  Cassie Frank; David U Himmelstein; Steffie Woolhandler; David H Bor; Sidney M Wolfe; Orlaith Heymann; Leah Zallman; Karen E Lasser
Journal:  Health Aff (Millwood)       Date:  2014-08       Impact factor: 6.301

4.  Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy.

Authors:  Nawaaz A Nathoo; Mahyar Etminan; Frederick S Mikelberg
Journal:  J Neuroophthalmol       Date:  2015-03       Impact factor: 3.042

5.  Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.

Authors:  Curtis E Margo; Dustin D French
Journal:  Am J Ophthalmol       Date:  2006-11-13       Impact factor: 5.258

6.  Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.

Authors:  Howard D Pomeranz; Abdhish R Bhavsar
Journal:  J Neuroophthalmol       Date:  2005-03       Impact factor: 3.042

7.  Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers.

Authors:  Dustin D French; Curtis E Margo
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.

Authors:  Ulka B Campbell; Alexander M Walker; Michael Gaffney; Kenneth R Petronis; Dana Creanga; Sheila Quinn; Barbara E K Klein; Alan M Laties; Michael Lewis; Ira D Sharlip; Francesca Kolitsopoulos; Brian J Klee; Jingping Mo; Robert F Reynolds
Journal:  J Sex Med       Date:  2014-10-31       Impact factor: 3.802
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.